GlassScriptPhysician profile
Dan Zhao
NPI 1306257472
$4,682.04
in general payments reported to CMS, 2019-2025
16 companies · $2,394 in 2025
The $2,394 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,047 · 2020: $266 · 2023: $363 · 2024: $613 · 2025: $2,394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,235 · Food and Beverage: $1,135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,235.09 |
| Food and Beverage | $1,134.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $2,765.64 | 2019-2025 | Onivyde |
| Trisalus Life Sciences, INC. | $663.72 | 2023-2024 | Trinav Infusion System |
| Genentech USA, INC. | $413.38 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $289.55 | 2019-2020 | |
| Lilly USA, LLC | $159.34 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $136.47 | 2019-2020 | |
| Genzyme Corporation | $35.40 | 2020 | |
| Exelixis INC. | $33.52 | 2019 | |
| Mirati Therapeutics, INC. | $30.90 | 2023 | Krazati |
| Octapharma USA, INC. | $28.00 | 2025 | Fibryga |
| Alexion Pharmaceuticals, INC. | $25.05 | 2019 | |
| Glaxosmithkline, LLC. | $25.00 | 2019 | |
| Celgene Corporation | $24.98 | 2020 | |
| Stemline Therapeutics INC. | $23.03 | 2020 | |
| Incyte Corporation | $16.03 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $12.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dan Zhao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.